Clinical Trial Update: Safety, Tolerability, and Clinical Effects of Twice-daily Doses of Cinacalcet (AMG 073) in Adults With Primary Hyperparathyroidism (HPT) [Phase 2]

View source ↗

Summary

Phase 2 trial update on twice-daily cinacalcet in adults with primary hyperparathyroidism evaluating safety, tolerability, and clinical effects.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperparathyroidism

Drugs mentioned

• cinacalcet (cinacalcet hydrochloride)

Snippet

Sponsor: Amgen | Conditions: Primary Hyperparathyroidism | Phase 2 | Status: COMPLETED